Evidence map›Paper›PMID 42032452›Full record

ArticleThe journal of headache and pain2026

Characterizing migraine burden and treatment response using nationwide smartphone app-based data in Korea.

Hong-Kyun Park, Yunha Noh, Min Kyung Chu, Ju-Young Shin, Yu-Jin Shin, Ha-Yeong Gil, Min-Taek Lee, Byung-Kun Kim

Abstract read
In one paragraph

Article in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hong-Kyun ParkDepartment of Neurology, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Gyeonggi-do, Republic of Korea.
Yunha NohCollege of Pharmacy, Chonnam National University, Gwangju, Republic of Korea.
Min Kyung ChuDepartment of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Ju-Young ShinDepartment of Biohealth Regulatory Science, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
Yu-Jin ShinPfizer Biopharmaceuticals Group, Pfizer Pharmaceuticals Korea Limited, Seoul, Republic of Korea.
Ha-Yeong GilPfizer Biopharmaceuticals Group, Pfizer Pharmaceuticals Korea Limited, Seoul, Republic of Korea.
Min-Taek LeePfizer Biopharmaceuticals Group, Pfizer Pharmaceuticals Korea Limited, Seoul, Republic of Korea.
Byung-Kun KimDepartment of Neurology, Nowon Eulji Medical Center, Eulji University School of Medicine, 68 Hangeulbiseok-Ro, Nowon-Gu, Seoul, 01830, South Korea. kbk1403@eulji.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMigraine is a major source of disability in Korea, yet many patients remain underdiagnosed or undertreated. Traditional epidemiological studies are limited by recall bias and incomplete patient-reported outcomes. App-based headache diaries offer real-time, repeated measures of symptoms and treatment, enabling large-scale assessment to better understand migraine burden and treatment response. This study aimed to evaluate the large-scale implementation of a nationally distributed smartphone "Headache Diary" mobile application and describe migraine burden, acute treatment response, and functional impairment in real-world practice in Korea.

methodsWe conducted a retrospective, non-interventional analysis using self-reported data from the nationwide "Headache Diary" mobile application, developed by the Korean Headache Society. We included users who submitted at least one headache report between December 2020 and January 2025. Migraine/probable migraine were identified using an algorithm based on medication use and ICHD-3 criteria, while the remaining participants were classified into a non-migraine group (including tension-type headache or unclassifiable headache disorders). Acute-treatment failure was defined as pain relief reported after 2 hours or no effect. We also analyzed clinical characteristics, acute treatment patterns, and functional impairment associated with headache attacks.

resultsOf 23,713 users, 17,913 (75.5%) had migraine or probable migraine. Migraine patients experienced more severe headache intensity (55.5% vs. 13.7%), higher rates of premonitory symptoms (67.7% vs. 29.5%), more frequent identification of triggers (89.9% vs. 61.2%), and greater use of acute medications (73.1% vs. 23.8%) compared to non-migraine users. Among 211,302 headache attacks analyzed, 155,894 attacks were migraine, and 96,742 attacks were available for acute treatment effect assessment. Of the 86,301 triptan-treated attacks, 40.3% resulted in acute treatment failure. Adolescents (10-19 years) showed the highest failure rate (62.1%). Notably, attacks with premonitory symptoms (odds ratio [OR] 0.91, 95% CI 0.89-0.94), aura (OR 0.79, 95% CI 0.75-0.83), or potential triggers (OR 0.93, 95% CI 0.91-0.96) had lower odds of treatment failure. Functional impairment was reported in 36.6% of attacks, most as decreased work or study efficiency (21.0%) and reduced household activity efficiency (17.2%).

conclusionsNationwide, app-based data revealed that migraine patients in Korea frequently experience severe attacks, premonitory symptoms, and triggers, with substantial rates of acute treatment failure and functional impairment. These findings highlight the need for earlier recognition and timely intervention and suggest that real-time digital platforms can provide valuable insights for patient-centered migraine management. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Cost of IllnessMigraine DisordersMobile ApplicationsSmartphoneSymptom BurdenAdolescentAdultFemaleHumansMaleMiddle AgedRepublic of KoreaRetrospective StudiesTreatment OutcomeYoung Adult

Identifiers

PMID42032452
PMCPMC13267421

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.